KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$30.7 million.

  • Biomarin Pharmaceutical's Income towards Parent Company fell 128.98% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $426.9 million for FY2024, which is 154.62% up from last year.
  • Biomarin Pharmaceutical's Income towards Parent Company amounted to -$30.7 million in Q3 2025, which was down 112.78% from $240.5 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Income towards Parent Company ranged from a high of $240.5 million in Q2 2025 and a low of -$57.9 million during Q4 2021.
  • For the 3-year period, Biomarin Pharmaceutical's Income towards Parent Company averaged around $90.0 million, with its median value being $88.7 million (2024).
  • Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 440.02% in 2021, then soared by 8,282.73% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Income towards Parent Company (Quarterly) stood at -$57.9 million in 2021, then surged by 99.57% to -$249,000 in 2022, then soared by 8,282.73% to $20.4 million in 2023, then soared by 513.22% to $124.9 million in 2024, then crashed by 128.98% to -$30.7 million in 2025.
  • Its Income towards Parent Company was -$30.7 million in Q3 2025, compared to $240.5 million in Q2 2025 and $185.7 million in Q1 2025.